Dallas, TX, United States of America

Anna Karolina Palucka

This inventor holds 7 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Baylor Research Institute, Agence Nationale De Recherches Sur Le Sida Et Les Hepatitis Virales. Active years: 2009-2018.

USPTO Granted Patents = 7 

% Patents Active = 71.4

 

 

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 29(Granted Patents)


Location History:

  • Dallas, TX (US) (2009 - 2018)
  • Avon, CT (US) (2018)

Company Filing History:


Years Active: 2009-2018

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Journey of Anna Karolina Palucka

Introduction: Anna Karolina Palucka is a pioneering inventor based in Dallas, Texas, known for her groundbreaking contributions to the field of biotechnology and medical research.

Latest Patents: Anna Karolina Palucka holds several patents related to novel immunotherapy treatments for cancer, innovative drug delivery systems, and cutting-edge diagnostic tools for autoimmune diseases.

Career Highlights: With a background in molecular biology and immunology, Palucka has worked at esteemed research institutions and biotech companies, leading teams in developing revolutionary therapies that have the potential to transform healthcare practices worldwide.

Collaborations: Throughout her career, Anna Karolina Palucka has collaborated with top scientists, medical professionals, and pharmaceutical companies to bring her innovative ideas from concept to reality. Her collaborative spirit has been instrumental in the success of many projects.

Conclusion: Anna Karolina Palucka's dedication to pushing the boundaries of science and medicine through her inventive spirit and collaborative efforts continues to inspire the next generation of inventors and researchers in the quest for groundbreaking solutions to complex health challenges.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…